Oxidative mechanisms in nigral cell death in Parkinson's disease

Movement Disorders

Volumn 13, Issue SUPPL. 1, 1998, Pages 24-34

  Jenner, P ^a,b  

^a Neurodegenerative Dis Res Centre   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cytochrome P450; Nitric oxide; Oxidative damage; Oxidative stress; Parkinson's disease

Indexed keywords

7 NITROINDAZOLE; BRAIN ENZYME; BRAIN PROTEIN; CYTOCHROME P450; FREE RADICAL; GLUTATHIONE; HYDROXYL RADICAL; IRON; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL TISSUE; BRAIN LEVEL; BRAIN NERVE CELL; CELL DEATH; CONFERENCE PAPER; DOPAMINERGIC TRANSMISSION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; CELL DEATH; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE MODELS, ANIMAL; FREE RADICALS; HUMANS; LIPID PEROXIDATION; MICE; NITRIC OXIDE; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA;

EID: 0031899172     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (100)

1. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
2. Gasser T, Wszolek ZK, Trofatter J, et al. Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994;36:387-396.
3. Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinson's disease: the story so far. Mov Disord 1998;13:212-220.
4. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:633-643.
5. Spina MB, Cohen G. Exposure of striatal synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988;247:502-507.
6. Vyas I, Heikkila RE, Nicklas WJ. Studies of the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. J Neurochem 1986;46:1501-1507.
7. Mizuno Y, Saitoh T, Sone N. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun 1987;143:971-976.
8. Scotcher KP, Irwin I, DeLanney LE, Langston JW, Di Monte D. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on ATP levels of mouse brain synaptosomes. J Neurochem 1990;54:1295-1301.
9. Chan P, DeLanney LE, Irwin I, Langston JW, DiMonte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 1991;57:348-351.
10. +) cause rapid ATP depletion in isolated hepatocytes. Biochem Biophys Res Commun 1986;137: 310-315.
11. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-798.
12. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 1993;87(suppl 146):6-13.
13. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996;47(suppl 3):S161-S170.
14. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
15. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.
16. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-346.
17. Dexter DT, Carayon A, Vidailhet M, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990;55:16-20.
18. Mann VM, Cooper JM, Daniel SE, Srai K, Marsden CD, Schapira AHV. Complex I, iron and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994;36:876-881.
19. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW. Infusion of iron into the rat substantia nigra. Nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 1993;35:67-82.
20. 125I-ferrotransfenrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 1993;60:2338-2341.
21. Faucheux BA, Nillesse N, Damier P, et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson's disease. Proc Natl Acad Sci USA 1995;92:9603-9607.
22. 125I-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. Brain Res 1997;749:170-174.
23. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
24. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
25. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
26. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
27. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994;36:356-361.
28. Barker JE, Heales SJR, Cassidy A, Bolanos JP, Land JM, Clark JB. Depletion of brain glutathione results in a decrease of glutathione reductase activity; an enzyme susceptible to oxidative damage. Brain Res 1996;716:118-122.
29. Mithofer K, Sandy MS, Smith MT, Di Monte D. Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Arch Biochem Biophys 1992;295:132-136.
30. Toffa S, Kunikowska GM, Zeng B-Y, Jenner P, Marsden CD. Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm 1997;104:67-75.
31. + toxicity in nigral dopaminergic neurones. Neuroreport 1996;7:921-923.
32. Andersen JK, Mo JQ, Horn DG, et al. Effect of buthionine sulfoximine, a synthesis inhibitor of the antioxidant glutathione, on the murine nigrostriatal neurons. J Neurochem 1996;67:2164-2171.
33. Seaton TA, Jenner P, Marsden CD. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. J Neural Transm 1996;103:315-329.
34. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827.
35. Schapira AHV, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (Complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145.
36. Mizuno Y, Matuda S, Yoshino H, Mori M, Hattori N, Ikebe S-I. An immunohistochemical study on α-ketogolutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994;35:204-210.
37. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov Disord 1994;9:125-138.
38. Mizuno Y, Ikebe S-I, Hattori N, et al. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. Biochim Biophys Acta 1995;1271:265-274.
39. +) in the pathogenesis of Parkinson's disease. Brain Res 1992;575:285-298.
40. Ikebe S-I, Tanaka M, Ohno K, et al. Increase of deleted mitochondrial DNA in the striatum in Parkinson's disease and senescence. Biocliem Biophys Res Commun 1990;170:1044-1048.
41. Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 1989;163:1450-1455.
42. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem 1990;55: 1810-1812.
43. Ikebe S-I, Tanaka M, Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Brain Res Mol Brain Res 1995; 28:281-295.
44. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:662-671.
45. Saggu H, Cooksey J, Dexter D, et al. A selective increase in paniculate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697.
46. Yoshida E, Mokuno K, Aoki S-I, et al. Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 1994;124:25-31.
47. Yoritaka A, Haltori N, Mori H, Kato K, Mizono Y. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease. J Neurol Sci 1997;148:181-186.
48. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
49. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9:92-97.
50. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydrbxynonenal protein adducts in Parkinson's disease. Proc Natl Acad Sci USA 1996;93:2696-2713.
51. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-1329.
52. Sanchez-Ramos JR, Överik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204.
53. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain. A selective increase in 8-hydroxyguanine in substantia nigra? J Neurochem 1997;69:1196-1203.
54. Spencer JPE, Jenner A, Chimel K, et al. CNA strand breakage and base modification induced by hydrogen peroxide treatment of human respiratory tract epithelial cells. FEBS Lett 1995;374:233-236.
55. Spencer JPE, Wong J, Jenner A, Aruoma OI, Cross CE, Halliwell B. Base modification and strand breakage in isolated calf thymus DNA and in DNA from human skin epidermal keratinocytes exposed to peroxynitrite or 3-morpholinosyndnonimine. Chem Res Toxicol 1996;9:1152-1158.
56. Reif DW, Simmons RD. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 1990;283:537-541.
57. Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AHV. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications of neurodegenerative diseases. FEBS Lett 1994;345:50-54.
58. Bolanos JP, Peuchen S, Heales SJR, Land JM, Clark JB. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J Neurochem 1994;63:910-916.
59. Bolanos JP, Heales SJR, Peuchen S, Barker JE, Land JM, Clark JB. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic Biol Med 1996;21: 995-1001.
60. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991;288: 481-487.
61. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991;349:414-418.
62. Sonsalla PK, Zeevalk GD, Manzino L, Giovanni A, Nicklas WJ. MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats. J Neurochem 1992;58:1979-1982.
63. Smith TS, Swerdlow RH, Parker WD, Bennett JP. Reduction of MPP+-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 1994;5:2598-2600.
64. Rose S, Hindmarsh JG, Silva MT, Hasham S, Jenner P. Inhibition of nitric-oxide synthase reduces MPP+-evoked hydroxyl radical formation in the rat striatum in vivo. Br J Pharmacol 1995;116:341P.
65. Schulz JB, Matthews RT, Muqit MMK, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995;64:936-939.
66. Przedborski S, Jackson Lewis V, Yokoyama R, Shibata R, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad USA 1996;93:4565-4655.
67. Hantraye P, Brouillet E, Ferrante R, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996;2:1017-1021.
68. MacKenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse 1997;26:301-306.
69. Kelly PAT, Thomas CL, Ritchie IM, Arbuthnott GW. Neuroscience 1994;59:13-20.
70. G-nitroarginine in brain in vivo and in vitro. Biochem Biophys Res Commun 1991;176:1136-1141.
71. MacKenzie GM, Rose S, Bland-Ward PA, Moore PK, Jenner P, Marsden CD. Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole. Neuroreport 1994;5:1993-1996.
72. Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 1997;10:364-368.
73. Connop BP, Boegman RJ, Beninger RJ, Jhamandas K. Malonate-induccd degeneration of basal forebrain cholinergic neurons: attenuation by lamotrigine, MK-801 and 7-nitroindazole. J Neurochem 1997;68:1191-1199.
74. +). Neurosci Lett 1990;117:129-133.
75. Hazell AS, Itzhak Y, Liu H, Norenberg MD. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J Neurochem 1997;68:2216-2219.
76. Jenner P, Olanow CW. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim M, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996:24-45.
77. Goode P, Werner R, Perl DP, Olanow CW. J Neurochem 1997. In press.
78. Warner M, Wyss A, Yoshida S, Gustafsson J-A. Cytochrome P450 enzymes in brain. In: Methods in Neurosciences, vol 22. New York, NY: Academic Press, 1994:51-66.
79. Riedl AG, Watts PM, Edwards RJ, Boobis AR, Jenner P, Marsden CD. Selective localization of P450 enzymes and NADPH-P450 oxidoreductase in rat basal ganglia using antipeptide antisera. Brain Res 1996;743:324-328.
80. Watts PM, Riedl AG, Douck DC, et al. The colocalization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase and glial fibrillary acidic protein. Neuroscience. In press.
81. Norris PJ, Hardwick JP, Emson PD. Regional distribution of cytochrome P450 2D1 in the rat central nervous system. J Comp Neurol 1996;366:244-258.
82. Gilham DE, Cairns W, Paine MJI, et al. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human fetal and adult brain by in situ hybridization. Xenobiotica 1997;27:111-125.
83. Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther 1996;277:685-690.
84. Kennedy NP, Tipton KF. Ethanol metabolism and alcoholic liver disease. Essays Biochem 1990;25:137-195.
85. Lieber C. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997;77:517-544.
86. Utti RJ, Snow BJ, Shinotoh H, et al. Parkinsonism induced by solvent abuse. Ann Neurol 1994;35:616-619.
87. Tetrud JW, Langston JW, Irwin I, Snow B. Parkinsonism caused by petroleum waste ingestion. Neurology 1994;44:1051-1054.
88. Pezzoli G, Antonini A, Barbieri S, et al. n-hexane-induced parkinsonism: pathosenic hypotheses. Mov Disord 1995;10:279-282.
89. Masotto C, Bisiani C, Camisasca C, et al. Effects of acute n-hexane and 2,5-hexanedione treatment on the striatal dopaminergic system in mice. J Neural Transm 1995;45(suppl):281-285.
90. Pezzoli G, Ricciadi S, Masotto C, Mariani CB, Carenzi A. n-hexane induces parkinsonism in rodents. Brain Res 1990;531: 355-357.
91. Ikeda M, Koizumi A, Kasahara M, Fujita H. Combined effects of n-hexane and toluene on norepinephrine and dopamine levels in rat brain tissues after long-term exposures. Bull Environ Contain Toxicol 1986;36:510-517.
92. Bredt DS, Snyder SL. Nitric oxide, a novel neuronal messenger. Neuron 1992;8:3-11.
93. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: a putative neural messenger. Science 1993;259:381-385.
94. Riedl AG, Watts PM, Brown CT, Jenner P. New insights into the cause of Parkinson's disease: P450 and haem oxygenase enzymes. Adv Neurol 1997. In press.
95. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992;40:755-784.
96. Deinum G, Stone JR, Babcock GT, Marietta MA. Binding of nitric oxide and carbon monoxide to soluble guanylate cyclase as observed with resonance Raman spectroscopy. Biochemistry 1996;35:1540-1547.
97. Zhuo M, Small A, Kandel ER, Hawkins RD. Nitric oxide and carbon monoxide produce activity-dependent long-term synaptic enhancement in hippocampus. Science 1993;260:1946-1949.
98. Maulik N, Engelman DT, Watanage M, et al. Nitric oxide/carbon monoxide. A molecular switch for myocardial preservation during ischemia. Circulation 1996;94(suppl II):II398-II406.
99. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274:1197-1198.
100. Polymeropoulos MH, Lavedant C, Leroy E. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.